AI Articles and Analysis about Research and development

Modern manufacturing stands to benefit from integrating AI. The potential benefits are numerous, from improving efficiency and productivity by automating repetitive tasks to reducing unplanned downtime and cutting down on repair costs through predictive maintenance.

This interview analysis is sponsored by BenchSci and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

Mobile technology, including smartphones and wearable devices, collects health-related data such as physical activity metrics (e.g., step counts, heart rate), sleep patterns, and self-reported health information through surveys and applications. 

Large enterprises' swift adoption of generative AI (GenAI) is driven by the quest for cost reduction and operational efficiency—but leaders risk falling behind competitors if these short-term gains stagnate without long-term innovation capabilities.

This interview analysis is sponsored by Medable and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.Although there is seemingly a constant stream of impressive headlines touting new drug treatments or potential cancer cures, medical breakthroughs occur at a slow pace. It can take upwards of 10 years from the time a medical breakthrough is discovered until it is eventually available in the market.Clinical trials are necessary to test the safety and effectiveness of new treatments. When clinical trials fail before they even start, medical breakthroughs are obviously delayed. Fortunately, the emergence of AI has the potential to change that situation. 

This interview analysis is sponsored by OneTrust and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

Gilead Sciences, a biopharmaceutical company founded in 1987, has emerged as a leader in the development of innovative therapies for a range of diseases, including HIV, liver diseases, and oncology. With a commitment to advancing the field of medicine, Gilead has increasingly recognized the vital role that AI plays in its operations. Gilead Sciences achieved an annual revenue of approximately $28.3 billion in 2024, driven by its robust portfolio, and employs around 18,000 people globally, reflecting its substantial size and reach within the biotech industry​.

As technology advances, the lines between mobile applications and medical devices are blurring in ways that have healthcare leaders, software developers, and regulators alike facing new and unprecedented challenges.